ANB101

ANB101 is a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs)

IND submitted; Phase 1 trial to initiate in healthy volunteers in Q1 2025

BDCA2 modulator of plasmacytoid dendritic cell (pDC) function

BDCA2 is a molecule specifically expressed on pDCs
ANB101 will potently inhibit interferon secretion and immune activation

Activated pDCs bridge innate and adaptive immunity

Secrete Type I IFN (1000x increase over other cell types)
Present antigens to adaptive immune system

pDCs enriched in tissue in rheumatology and other inflammatory diseases

BDCA2 modulator mechanistic proof-of-concept (Biogen’s litifilimab) in SLE / CLE

ANB101: BDCA2 modulator

Potent and sustained internalization of BDCA2 on pDC cell surface
Profound inhibition of interferon secretion reduces inflammation
Preserves pDCs for potential tolerogenic effects

Note: ANB101 (formerly known as CBS004) was in-licensed from Centessa Pharmaceuticals. Has completed NHP tox studies and P1 clinical material available.